| [1] |
Krop IE,Lorusso P,Miller KD,et al. Primary results from EMILIA,a phase Ⅲstudy of trastuzumab emtansine (T-DM1)versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC)previously treated with trastuzumab (T) and a taxane[EB/OL]. [2012-07-18]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? &vmview=abst_detail_view&confID=114&abstractID=98675.
|
| [2] |
Robidoux A, Tang G,Rastogi P,et al. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41[EB/OL]. [2012-07-18].http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? &vmview=abst_detail_view & confID=114&abstractID=99368.
|
| [3] |
Gelmon KA, Boyle F, Kaufman B, et al. Open-label phase Ⅲrandomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919[EB/OL]. [2012-07-18].http:/ /www.asco.org/ASCOv2/Meetings/Abstracts? &vmview=abst_detail_view&confID=114&abstractID=102986.
|
| [4] |
Swain SM, Tang G, Geyer CE, et al. NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dosedense (DD) AC →paclitaxel (P) plus gemcitabine (G) with DD AC →P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer[EB/OL]. [2012-07-18]. http:/ /www.asco.org/ASCOv2/Meetings/Abstracts? &vmview=abst_detail_view&confID=114&abstractID=98794.
|
| [5] |
Martin M, Lluch A, Ruiz A, et al. Randomized phase Ⅲstudy of adjuvant chemotherapy for high-risk, node-negative breast cancer (BC) comparing FAC with FAC followed by weekly paclitaxel: First efficacy analysis of the GEICAM/2003-02 trial [EB/OL]. [2012-07-18]. http:/ /www. asco. org/ASCOv2/Meetings/Abstracts? &vmview = abst _ detail _view&confID=114&abstractID=99535.
|
| [6] |
Rugo HS, Barry WT, Moreno-Aspitia A, et al. CALGB 40502/NCCTG N063H: Randomized phase Ⅲtrial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC) [EB/OL]. [2012-07-18].http:/ /www.asco.org/ASCOv2/Meetings/Abstracts? &vmview=abst_detail_view&confID=114&abstractID=99475.
|
| [7] |
Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100[J].J Clin Oncol,2008,26(28):4672-4678.
|
| [8] |
Im YH, Park YH, Jung KH, et al. A phase Ⅲ, multicenter, randomized trial of maintenance versus observation after achieving clinical response in patients with metastatic breast cancer who received six cycles of gemcitabine plus paclitaxel as first-line chemotherapy (KCSG-BR 0702,NCT00561119) [EB/OL]. [2012-07-18].http:/ /www.asco.org/ASCOv2/Meetings/Abstracts? &vmview=abst_detail_view&confID=114& abstractID=97032.
|